Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of July 2005
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12
BGC Centre
28
The
Esplanade
Perth
WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
x Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No
x
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
| pSivida Limited | ||
| |
|
|
| Date: July 25, 2005 | By: | /s/ Aaron Finlay |
| Aaron Finlay | ||
| Chief Financial Officer and Company Secretary | ||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
pSivida
appoints CEO of Chugai Pharma USA as a Non-Executive
Director.
Business
Development Focus
|
|
|||
| ASX/MEDIA RELEASE |
25th
July 2005
|
||
pSivida
appoints CEO of Chugai Pharma USA as a Non-Executive
Director.
Business
Development Focus
Global
nanotechnology company pSivida Limited (ASX:PSD,
NASDAQ:PSDV, Xetra:PSI)
is
pleased to announce the appointment of Dr. David J. Mazzo as a Non-executive
Director of the company, based in New Jersey, USA.
As
President and CEO of Chugai Pharma USA, Dr. Mazzo brings his significant
business development experience and pharmaceutical network to the Board.
His
appointment follows pSivida’s recent NASDAQ listing and will further assist
pSivida’s strategy to increase its visibility in the US pharmaceutical and
capital markets.
Chugai
Pharma USA is part of the Roche group of companies and is a subsidiary of
Chugai
Pharmaceutical Company Limited (Japan), a global research-based pharmaceutical
company with sales in 2001 of US$1.7 billion.
Dr.
Mazzo
is
recognized for his strong scientific and regulatory expertise with broad
technical and managerial experience gained from working in a variety of
multi-cultural and multi-lingual environments in the USA, Europe and
Asia.
Dr.
Mazzo
holds a Bachelor of Arts with Honors (Interdisciplinary Humanities) and a
B.S.
with Honors in Chemistry from Villanova University, as well as a Master of
Science in Chemistry and a Ph.D in Analytical Chemistry from the University
of
Massachusetts. He complemented his American education as a Research Fellow
at
the École Polytechnique Fédérale de Lausanne, Switzerland.
pSivida’s
Managing Director Mr Gavin Rezos said, “We are very fortunate to have David join
the Board. David brings a unique and powerful blend of scientific and business
skills that will greatly assist pSivida’s expansion in the US market.”
Dr.
Mazzo
has published often and is frequently invited to present at international
pharmaceutical conferences. He served as a member of the Nasal Drug Products
subcommittee of the FDA Advisory Committee for Pharmaceutical Science and
presently serves as an advisor to a number of academic and investment
organisations.
The
pSivida Board engaged Tamara P. Davis, Managing Director, Corporate Governance
Practice at Levin & Company, Inc.
Boston., Massachusetts,
to
assist in this important Board Director recruitment.
-ENDS-
Released
by:
|
pSivida
Limited
Brian
Leedman
Investor
Relations
pSivida
Limited
Tel:
+ 61 8 9327 5099
brianl@psivida.com
|
US
Public Relations
Beverley
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 9 1100 ext. 12
bjedynak@janispr.com
|
UK
& Europe Public Relations
Mark
Swallow, PhD / Helena Podd
Citigate
Dewe Rogerson
Tel:
+44 (0)20 7282 2948 / 2867
mark.swallow@citigatedr.co.uk
|
NOTES
TO EDITORS:
pSivida
Limited
pSivida
is a global nanotechnology company committed to the biomedical sector and
the
development of products in healthcare. The company’s focus is the development
and commercialisation of a modified form of silicon (porosified or
nano-structured silicon) known as BioSilicon™. As a new and exciting
biocompatible material, BioSilicon™ offers multiple potential applications
across the high growth healthcare sector, including controlled release drug
delivery, targeted cancer therapies (including brachytherapy and localized
chemotherapy), tissue engineering and orthopedics. Potential diagnostics
applications are being developed through its subsidiary AION Diagnostics
Limited.
pSivida
owns the intellectual property rights to BioSilicon™ for use in or on humans and
animals. The IP portfolio consists of 26 patent families, 29 granted patents
and
over 80 patent applications. The core patent, which recognises BioSilicon™ as a
biomaterial was granted in the UK in 2000 and in the US in 2001.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and in
Germany on the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida’s shares also trade in the United Kingdom on the OFEX International
Market Service (IMS) under the ticker symbol PSD.
The
Company’s strategic partner and largest shareholder is the QinetiQ group, the
largest science and technology company in Europe. QinetiQ is the former UK
government Defence Evaluation Research Agency and was instrumental in
discovering BioSilicon™. pSivida enjoys a strong relationship with QinetiQ
having access to its cutting edge research and development facilities. For
more
information on QinetiQ visit www.qinetiq.com.
For
more
information visit www.psivida.com
This
document contains forward-looking statements that involve risks and
uncertainties. Although we believe that the expectations reflected in such
forward-looking statements are reasonable at this time, we can give no
assurance
that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Actual results could differ materially from those anticipated
in
these forward-looking statements due to many important factors including:
our
failure to develop applications for BioSiliconTM
due to
regulatory, scientific or other issues. Other reasons are contained in
cautionary statements in the Registration Statement on Form 20-F filed
with the
U.S. Securities and Exchange Commission, including, without limitation,
under
Item 3.D, "Risk Factors" therein. We do not undertake to update
any oral or
written forward-looking statements that may be made by or on behalf of
pSivida.